BACKGROUND: Implantable cardioverter-defibrillator (ICD) shocks are potentially associated with myocardial injury, altered hemodynamics, apoptosis, and inflammatory signaling. Their precise cellular impact can be explored after defibrillation testing (DFT) via biomarkers. We evaluated changes in biomarkers after ICD shocks during DFT. METHODS: We prospectively enrolled outpatients presenting for first implantation of a cardiac device. Biomarkers indicative of myocardial injury, inflammation, and apoptosis were measured before and after implantation, and compared between patients receiving DFT (DFT+) to those not (DFT-). RESULTS: Sixty-three patients were enrolled, 40 in the DFT+ group and 23 in the DFT- group. Average levels of troponin I, hsCRP, Calprotectin, N-terminal pro B-type natriuretic peptide (NTproBNP), and sFas increased by >50% after cardiac device implantation compared to baseline. Increase in troponin never exceeded the 50-fold upper limit of normal (2 ng/mL). Troponin trended higher in the DFT+ group at 8 hours (median 0.18 ng/mL, interquartile range [IQR] 0.11-0.48) versus the DFT- group (0.10 ng/mL, IQR 0.06-0.28, P = 0.0501); NTproBNP had a similar trend (P = 0.0581). sFas significantly increased in the DFT+ group from baseline (median 4663 pg/mL, IQR 2908-5679) to 24 hours (5039 pg/mL, IQR 3274-6261; P = 0.0338) but not in the DFT- group (P = 0.4705). CONCLUSION: DFT testing is associated with acutely increased plasma levels of troponin and sFas, a biomarker of apoptosis, along with a trend toward higher NTproBNP.
BACKGROUND: Implantable cardioverter-defibrillator (ICD) shocks are potentially associated with myocardial injury, altered hemodynamics, apoptosis, and inflammatory signaling. Their precise cellular impact can be explored after defibrillation testing (DFT) via biomarkers. We evaluated changes in biomarkers after ICD shocks during DFT. METHODS: We prospectively enrolled outpatients presenting for first implantation of a cardiac device. Biomarkers indicative of myocardial injury, inflammation, and apoptosis were measured before and after implantation, and compared between patients receiving DFT (DFT+) to those not (DFT-). RESULTS: Sixty-three patients were enrolled, 40 in the DFT+ group and 23 in the DFT- group. Average levels of troponin I, hsCRP, Calprotectin, N-terminal pro B-type natriuretic peptide (NTproBNP), and sFas increased by >50% after cardiac device implantation compared to baseline. Increase in troponin never exceeded the 50-fold upper limit of normal (2 ng/mL). Troponin trended higher in the DFT+ group at 8 hours (median 0.18 ng/mL, interquartile range [IQR] 0.11-0.48) versus the DFT- group (0.10 ng/mL, IQR 0.06-0.28, P = 0.0501); NTproBNP had a similar trend (P = 0.0581). sFas significantly increased in the DFT+ group from baseline (median 4663 pg/mL, IQR 2908-5679) to 24 hours (5039 pg/mL, IQR 3274-6261; P = 0.0338) but not in the DFT- group (P = 0.4705). CONCLUSION: DFT testing is associated with acutely increased plasma levels of troponin and sFas, a biomarker of apoptosis, along with a trend toward higher NTproBNP.
Authors: Claude S Elayi; Matthew G Whitbeck; Richard Charnigo; Jignesh Shah; Tracy E Macaulay; Gustavo Morales; John C Gurley; Bahram Kakavand; Sergio Thal; Chi Keong Ching; Yaariv Khaykin; Atul Verma; Conor Barrett; Rong Bai; Luigi Di Biase; Abhijit Patwardhan; David J Moliterno; Andrea Natale Journal: Circ Arrhythm Electrophysiol Date: 2011-04-21
Authors: Héloise Cardinal; François Madore; James M Brophy; Lawrence Joseph; Marie-Josée Hébert; Sooyeon Min; Luce Boyer; Peter Bogaty Journal: Int J Cardiol Date: 2014-03-22 Impact factor: 4.164
Authors: Jeff S Healey; Stefan H Hohnloser; Michael Glikson; Jorg Neuzner; Phillipe Mabo; Xavier Vinolas; Josef Kautzner; Gilles O'Hara; Lieselot VanErven; Fredrik Gadler; Janice Pogue; Ursula Appl; Jim Gilkerson; Thierry Pochet; Kenneth M Stein; Bela Merkely; Susan Chrolavicius; Brandi Meeks; Csaba Foldesi; Bernard Thibault; Stuart J Connolly Journal: Lancet Date: 2015-02-23 Impact factor: 79.321
Authors: Jeanne E Poole; George W Johnson; Anne S Hellkamp; Jill Anderson; David J Callans; Merritt H Raitt; Ramakota K Reddy; Francis E Marchlinski; Raymond Yee; Thomas Guarnieri; Mario Talajic; David J Wilber; Daniel P Fishbein; Douglas L Packer; Daniel B Mark; Kerry L Lee; Gust H Bardy Journal: N Engl J Med Date: 2008-09-04 Impact factor: 91.245
Authors: Min-Shan Tsai; Wanchun Tang; Shijie Sun; Hao Wang; Gary Freeman; Wen-Jone Chen; Max Harry Weil Journal: Crit Care Med Date: 2009-08 Impact factor: 7.598
Authors: Verena Semmler; Jürgen Biermann; Bernhard Haller; Clemens Jilek; Nikolaus Sarafoff; Carsten Lennerz; Hrvoje Vrazic; Bernhard Zrenner; Stefan Asbach; Christof Kolb Journal: PLoS One Date: 2015-07-24 Impact factor: 3.240
Authors: Irene Kirolos; David Jones; Kirstin Hesterberg; Charles Yarn; Rami N Khouzam; Yehoshua C Levine Journal: Curr Treat Options Cardiovasc Med Date: 2019-08-08